[February 24, 2017]

Global Pharmacogenomics Partnering Terms and Agreements Analysis 2010-2017 - Research and Markets

Research and Markets has announced the addition of the "Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017" report to their offering.

The Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors.

Pharmacogenomics focuses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug's efficacy or toxicity.

Understanding te flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight.

Key benefits:

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of pharmacogenomics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of pharmacogenomics agreements with real life case studies

Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies

Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Key Topics Covered:

Executive Summary

1. Introduction

2. Trends in Pharmacogenomics dealmaking

3. Leading Pharmacogenomics deals

4. Most active Pharmacogenomics dealmakers

5. Pharmacogenomics contracts dealmaking directory

6. Pharmacogenomics dealmaking by technology type

7. Partnering resource center

For more information about this report visit http://www.researchandmarkets.com/research/p83lch/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005606/en/

[ Back To TMCnet.com's Homepage ]